KRAS G12V-derived peptide bound to HLA-A*11:01 (KRAS G12V/HLA-A*11:01)

The KRAS G12V-derived peptide bound to HLA-A*11:01 is a tumor-specific neoantigen complex consisting of a mutated fragment of the KRAS protein (where glycine at position 12 is replaced by valine) presented by the Human Leukocyte Antigen (HLA) allele A*11:01. KRAS is a small GTPase that acts as a molecular switch in signaling pathways like MAPK/ERK, and the G12V mutation leads to constitutive activation, driving oncogenesis in various cancers including pancreatic, colorectal, and lung adenocarcinoma (Source: PubMed, PMID: 33009416). Because this specific peptide-MHC complex is absent on healthy cells, it serves as a highly selective target for immunotherapy, particularly T-cell receptor (TCR) engineered T-cell therapies (Source: Affini-T Therapeutics). Drugs targeting this complex, such as AFNT-211, utilize engineered TCRs to recognize the mutant peptide in the context of the HLA-A*11:01 molecule, triggering a cytotoxic immune response against the tumor (Source: ClinicalTrials.gov, NCT05592600). This approach is particularly relevant for patients of East Asian descent, where the HLA-A*11:01 allele is highly prevalent (Source: Allele Frequency Net Database).

Other names

KRAS G12V/HLA-A*11:01KRAS G12V neoantigenHLA-A*11:01-presented KRAS G12V peptideKRAS G12V-HLA-A11 complex

T-cell receptor (TCR) mediated recognition and subsequent cytotoxic T-lymphocyte activation against cells presenting the KRAS G12V neoantigen.